Edition:
India

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

4.90USD
8:14pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.90
Open
$4.90
Day's High
$4.90
Day's Low
$4.90
Volume
38,135
Avg. Vol
71,869
52-wk High
$4.90
52-wk Low
$2.45

Chart for

About

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene... (more)

Overall

Beta: --
Market Cap(Mil.): $153.67
Shares Outstanding(Mil.): 43.29
Dividend: --
Yield (%): --

Financials

BRIEF-Adverum Biotechnologies Provides 2018 Outlook

* ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017.

04 Jan 2018

BRIEF-Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies

* HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING Source text for Eikon: (http://bit.ly/2iwSEnw) Further company coverage:

07 Dec 2017

BRIEF-Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial

* ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY

05 Dec 2017

BRIEF-‍Adage Capital Partners Reports A 5.55 Percent Passive Stake In Adverum Biotechnologies As Of Nov 17, 2017

* ‍ADAGE CAPITAL PARTNERS GP, L.L.C REPORTS A 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF NOVEMBER 17, 2017 - SEC FILING​ Source text: (http://bit.ly/2hXgpom) Further company coverage:

27 Nov 2017

BRIEF-Adverum Biotechnologies posts Q3 loss of $0.32 per share

* Adverum biotechnologies reports third quarter 2017 financial results and provides corporate update

09 Nov 2017

BRIEF-Adverum Biotechnologies says has increased size of board to eight members

* Adverum Biotechnologies Inc - increased size of board to eight members - SEC filing Source text: [http://bit.ly/2eKPWc0] Further company coverage:

08 Sep 2017

BRIEF-Adverum Biotechnologies files for mixed shelf of up to $150 mln

* Adverum Biotechnologies Inc files for mixed shelf of up to $150 million - ‍​sec filing Source text: (http://bit.ly/2wyLc11) Further company coverage:

11 Aug 2017

BRIEF-Adverum Biotechnologies Q2 loss per share $0.27

* Adverum Biotechnologies reports second quarter 2017 financial results and provides update

09 Aug 2017

Earnings vs. Estimates